Kelly Shi
Analyst
Jefferies
Equibles does not estimate personal net worth.
About Kelly Shi
Kelly Shi is recorded as Analyst at Jefferies. Kelly Shi has spoken on 3 earnings calls across 2 companies, most recently for Summit Therapeutics Inc. on May 1, 2025. Those appearances were for Summit Therapeutics Inc. (SMMT) and Ptc Therapeutics, Inc. (PTCT). The companies whose calls Kelly Shi spoke on are classified in the Healthcare sector.
Kelly Shi on recent calls
“And my first question is for Harmony 3, the chemo combo trial in front line. Do you set the enrollment target for squamous and non-squamous versus non-squamous patients?”
“I also have a couple for the PIVOT-HD trial. Firstly, from the 12 months to 24 months, what kind of improvement do you expect on total motor score and UHDRS and maybe also the TFC, the Total Functional Capacity?”
“Congrats on the progress. thank you for taking my questions maybe a couple of questions uh how many trial global trial design um so regarding the polling assumptions on both pfs and os should we assume it is designed based on the total 420 patients but not a subgroup of ex-china patients yeah this is alan yang”
Affiliation history
-
Jefferies
Analyst
Source not stated
Current